Drug Profile
Enterovirus A vaccine - Beijing Luzhu Biopharmaceutical Co., Ltd.
Alternative Names: E71 vaccine - Beijing Luzhu Biopharmaceutical Co., Ltd.; Enterovirus A infection vaccine - Beijing Luzhu Biopharmaceutical Co., Ltd.; EV 71 vaccine; EV71 inactivated vaccine; Hand, foot and mouth disease (HFMD) vaccine - Beijing Luzhu Biopharmaceutical Co., Ltd.; HFMD vaccine - Beijing Luzhu Biopharmaceutical Co., Ltd.Latest Information Update: 28 Jun 2023
Price :
$50
*
At a glance
- Originator Beijing Zhifei Lvzhu Biopharmaceutical
- Class Enterovirus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Enterovirus A infections
Most Recent Events
- 24 Oct 2022 Enterovirus A vaccine is still in phase II trials for Enterovirus A infection (In Infants, In Children, Prevention) in China (IM) (NCT05913024)
- 24 Oct 2022 Beijing Luzhu Biopharmaceutical Co., Ltd. completes a phase-II clinical trial in Enterovirus A infections (In children, In infants, Prevention) in China (IM) (NCT05913024)
- 19 Oct 2021 Phase-II clinical trials in Enterovirus A infections (In children, In infants, Prevention) in China (IM) (NCT05913024)